Although biologics and biosimilar drugs only represent 2% of U.S. prescription volume, these naturally sourced medications have recently become the focus of much discussion across healthcare channels. Biologics – often considered specialty drugs – have accounted for as much as 37% of drug spending in a single year. Read more about how Biologics and Biosimilars help fight chronic disease as well as the difference between Generics and Biosimilars.
Related Posts
Early Phase Trial Data Show Novel Weight Loss Drug May Have Longer Lasting Effect Than GLP-1 Agonists
- admin
- February 8, 2024
- 0
Image credit: Daniel Krasoń | stock.adobe.com Amgen’s novel weight loss drug candidate maridebart cafraglutide (MariTide) showed significant promise in a Phase I trial (NCT04478708), with […]
FDA Fast Tracks Ovarian Cancer Drug Currently in Phase II Trial
- admin
- January 13, 2024
- 0
Image credit: blueringmedia | stock.adobe.com The FDA has granted Fast Track Designation (FTD) to RemeGen Co. Ltd’s mesothelin-targeting antibody-drug conjugate (ADC) RC88 to treat patients […]
Considerations for Integrating Artificial Intelligence
- admin
- June 29, 2024
- 0
ACT: What should industry stakeholders be keeping top of mind when implementing artificial intelligence (AI) into their workflows? Lacroix: When we started thinking, or when […]